Insulin homeostasis in the extremely low birth weight infant

P Mena1, A Llanos, R Uauy

  • 1Hospital Dr. Sótero del Rio and Institute of Nutrition and Food Technology, University of Chile, Santiago. pmena@uec.inta.uchile.cl

Seminars in Perinatology
|January 10, 2002
PubMed

Insights

Extremely low birth weight infants often experience hyperglycemia due to impaired glucose regulation. Insulin therapy shows promise for managing this condition, but further research is needed to confirm its effectiveness in clinical practice.

Area of Science:

  • Neonatal Medicine
  • Endocrinology
  • Metabolic Disorders

Background:

  • Extremely low birth weight (ELBW) infants face nutritional challenges, leading to increased glucose intolerance.
  • Hyperglycemia in ELBW infants is linked to an impaired ability to suppress gluconeogenesis during glucose infusion.
  • Potential causes include pancreatic insulin secretion issues and hepatic insulin resistance.

Purpose of the Study:

  • To explore the mechanisms behind hyperglycemia in ELBW infants.
  • To evaluate the potential role of insulin in managing glucose intolerance in this population.

Main Methods:

  • Review of existing literature on glucose metabolism and insulin's effects in ELBW infants.
  • Analysis of studies investigating continuous insulin infusion for hyperglycemia treatment.

Main Results:

  • ELBW infants exhibit a higher capacity for glucose oxidation.
  • Insulin may enhance glucose utilization and improve glucose tolerance.
  • Continuous insulin infusion appears safe for treating hyperglycemia in ELBW infants, according to current data.

Conclusions:

  • The findings support considering insulin for preventing and treating hyperglycemia in ELBW infants.
  • Further rigorous clinical trials are essential to establish the efficacy of insulin treatment before routine adoption.

Related Concept Videos

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...